Journal of the Association of Nurses in AIDS Care
Volume 21, Issue 6 , Pages 489-502 , November 2010

Strategies to Promote Adherence to Antiretroviral Therapy Applied by Dutch HIV Nurse Consultants: A Descriptive Qualitative Study

References 

  1. Amico KR, Harman JJ, Johnson BT. Efficacy of antiretroviral therapy adherence interventions: A research synthesis of trials, 1996 to 2004. Journal of Acquired Immune Deficiency Syndrome. 2006;41:285–297
  2. Ananworanich J, Gayet-Ageron A, Le BM, Prasithsirikul W, Chetchotisakd P, Kiertiburanakul S, et al. CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: Results of the Staccato randomised trial. Lancet. 2006;368:459–465
  3. Bangsberg DR, Perry S, Charlebois ED, Clark RA, Roberston M, Zolopa AR, et al. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS. 2001;15:1181–1183
  4. Clumeck, N., Dedes, N., Pozniak, A., & Raffi, F. (2008). Guidelines: Clinical management and treatment of HIV-infected adults in Europe. Retrieved from http://www.europeanaidsclinicalsociety.org/guidelinespdf/1_Treatment_of_HIV_Infected_Adults.pdf
  5. Danel C, Moh R, Minga A, Anzian A, Ba-Gomis O, Kanga C, et al. CD4-guided structured antiretroviral treatment interruption strategy in HIV-infected adults in West Africa (Trivacan ANRS 1269 trial): A randomised trial. Lancet. 2006;367:1981–1989
  6. de Bruin M, Viechtbauer W, Hospers HJ, Schaalma HP, Kok G. Standard care quality determines treatment outcomes in control groups of HAART-adherence intervention studies: Implications for the interpretation and comparison of intervention effects. Health Psychology. 2009;28:668–674
  7. In:  Denzin N editors. Sociological methods: A sourcebook. 5th ed.. New Brunswick, NJ: Transaction; 1970;
  8. El-Sadr WM, Lundgren JD, Neaton JD, Gordin F, Abrams D, Arduino RC, et al. CD4+ count-guided interruption of antiretroviral treatment. New England Journal of Medicine. 2006;355:2283–2296
  9. Gazzard BG. British HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Medicine. 2008;9:563–608
  10. Geng EH, Deeks SG. CD4+ T cell recovery with antiretroviral therapy: More than the sum of the parts. Clinical Infectious Diseases. 2009;48:362–364
  11. Gerbert B, Bronstone A, Clanon K, Abercrombie P, Bangsberg D. Combination antiretroviral therapy: Health care providers confront emerging dilemmas. AIDS Care. 2000;12:409–421
  12. Hogg RS, Heath K, Bangsberg D, Yip B, Press N, O'Shaughnessy MV, et al. Intermittent use of triple-combination therapy is predictive of mortality at baseline and after 1 year of follow-up. AIDS. 2002;16:1051–1058
  13. Kuckartz U. winMAX scientific text analysis for the social science. Berlin, Germany: BSS; 1998;
  14. Lima VD, Geller J, Bangsberg DR, Patterson TL, Daniel M, Kerr T, et al. The effect of adherence on the association between depressive symptoms and mortality among HIV-infected individuals first initiating HAART. AIDS. 2007;21:1175–1183
  15. Liu H, Miller LG, Hays RD, Golin CE, Wu T, Wenger NS, et al. Repeated measures longitudinal analyses of HIV virologic response as a function of percent adherence, dose timing, genotypic sensitivity, and other factors. Journal of Acquired Immune Deficiency Syndromes. 2006;41:315–322
  16. McNabb J, Ross JW, Abriola K, Turley C, Nightingale CH, Nicolau DP. Adherence to highly active antiretroviral therapy predicts virologic outcome at an inner-city human immunodeficiency virus clinic. Clinical Infectious Diseases. 2001;33:700–705
  17. Mills EJ, Nachega JB, Bangsberg DR, Singh S, Rachlis B, Wu P, et al. Adherence to HAART: A systematic review of developed and developing nation patient-reported barriers and facilitators. PLoS Medicine. 2006;3:e438;Retrieved from http://www.plosmedicine.org/article/info:doi/10.1371/journal.pmed.0030438
  18. Mocroft A, Ledergerber B, Katlama C, Kirk O, Reiss P, d'Arminio Monforte A, et al. Decline in the AIDS and death rates in the EuroSIDA study: An observational study. Lancet. 2003;362:22–29
  19. Panel on Antiretroviral Guidelines for Adults and Adolescents. (2009). Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Retrieved from http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf
  20. Parruti G, Manzoli L, Toro PM, D'Amico G, Rotolo S, Graziani V, et al. Long-term adherence to first-line highly active antiretroviral therapy in a hospital-based cohort: Predictors and impact on virologic response and relapse. AIDS Patient Care and STDS. 2006;20:48–56
  21. Robbins GK, Spritzler JG, Chan ES, Asmuth DM, Gandhi RT, Rodriguez BA, et al. Incomplete reconstitution of T cell subsets on combination antiretroviral therapy in the AIDS Clinical Trials Group protocol 384. Clinical Infectious Diseases. 2009;48:350–361
  22. Simoni JM, Amico KR, Pearson CR, Malow R. Strategies for promoting adherence to antiretroviral therapy: A review of the literature. Current Infectious Diseases Report. 2008;10:515–521
  23. Stone VE. Strategies for optimizing adherence to highly active antiretroviral therapy: Lessons from research and clinical practice. Clinical Infectious Diseases. 2001;33:865–872
  24. Stone VE. Enhancing adherence to antiretrovirals: Strategies and regimens. Medscape General Medicine. 2002;4(22):Retrieved from http://www.medscape.com/viewarticle/438193
  25. van Meijel B, Gamel C, van Swieten-Duijfjes B, Grypdonck MH. The development of evidence-based nursing interventions: Methodological considerations. Journal of Advanced Nursing. 2004;48:84–92
  26. Vervoort SC, Borleffs JC, Hoepelman AI, Grypdonck MH. Adherence in antiretroviral therapy: A review of qualitative studies. AIDS. 2007;21:271–281
  27. Vervoort, S.C., Dijkstra, B.M., Hazelzet, E.E., Grypdonck, M.H., Hoepelman, A.I., & Borleffs, J.C. (in press). The role of HIV nursing consultants in the care of HIV-infected patients in Dutch hospital outpatient clinics. Patient Education and Counseling. doi:10.1016/j.pec.2009.11.016
  28. World Health Organization. (2003). Adherence to long-term therapy: Evidence for action. Retrieved from http://www.who.int/chronic_conditions/adherencereport/en/

 Andy I. M. Hoepelman reports the following relationships: consultancies with Bristol-Myers Squibbb, consultancies and research support with Gilead, consultancies with Novartis, research support and consultancies with Roche, consultancies with Tibotec, and research support and consultancies with Pfizer. The other authors report no real or perceived vested interests that relate to this article (including relationships with pharmaceutical companies, biomedical device manufacturers, grantors, or other entities whose products or services are related to topics covered in this manuscript) that could be construed as a conflict of interest.

PII: S1055-3290(10)00048-8

doi: 10.1016/j.jana.2010.03.002

Journal of the Association of Nurses in AIDS Care
Volume 21, Issue 6 , Pages 489-502 , November 2010

Article Tools